-$0.07 Earnings Per Share Expected for Oragenics, Inc. (NASDAQ:OGEN) This Quarter

Wall Street brokerages predict that Oragenics, Inc. (NASDAQ:OGEN) will post earnings of ($0.07) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Oragenics’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.07). Oragenics posted earnings of ($0.38) per share during the same quarter last year, which would suggest a positive year over year growth rate of 81.6%. The firm is scheduled to issue its next earnings results on Monday, August 12th.

On average, analysts expect that Oragenics will report full-year earnings of ($0.30) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.28). For the next financial year, analysts expect that the firm will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.31) to ($0.23). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Oragenics.

Oragenics (NASDAQ:OGEN) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03).

Separately, HC Wainwright reissued a “buy” rating on shares of Oragenics in a research report on Friday, April 26th.

Shares of NASDAQ OGEN traded down $0.01 during mid-day trading on Monday, reaching $0.48. The company had a trading volume of 229,888 shares, compared to its average volume of 1,331,524. The business has a fifty day simple moving average of $0.48. Oragenics has a 12-month low of $0.38 and a 12-month high of $3.74.

Oragenics Company Profile

Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Recommended Story: Hold Rating

Get a free copy of the Zacks research report on Oragenics (OGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.